[144] Kyverna Therapeutics, Inc. SEC Filing
Filing Impact
Filing Sentiment
Form Type
144
Rhea-AI Filing Summary
KYTX filed a Form 144 reporting the proposed sale of 17,578 shares of Common Stock via a stock option exercise to be effected on 04/07/2026 for cash. The filing also discloses a prior sale of 16,634 shares on 03/31/2026 for $140,404.27.
Positive
- None.
Negative
- None.
Key Figures
Proposed shares to be sold: 17,578 shares
Reported value associated: $162,636.93
Prior sale - shares: 16,634 shares
+1 more
4 metrics
Proposed shares to be sold
17,578 shares
stock option exercise scheduled 04/07/2026
Reported value associated
$162,636.93
listed alongside 17,578 shares on 04/07/2026 row
Prior sale - shares
16,634 shares
sold by Daniel Spiegelman on 03/31/2026
Prior sale - proceeds
$140,404.27
proceeds reported for 16,634-share sale on 03/31/2026
Key Terms
Form 144, Stock Option Exercise, Issuer, Cash
4 terms
Form 144 regulatory
"144: Securities To Be Sold"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Stock Option Exercise financial
"Common | 04/07/2026 | Stock Option Exercise"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
Issuer financial
"Stock Option Exercise | Issuer"
Cash financial
"04/07/2026 | Cash"